Levemir Flextouch (Insulin Detemir)

Levemir Flextouch is a basal insulin analog that acts on the endocrine system to manage chronic hyperglycaemia in diabetes.

• Type 1 diabetes mellitus: provides long‑acting insulin to maintain fasting glucose levels.
• Type 2 diabetes mellitus: supplies basal insulin to complement oral agents and improve overall glycaemic control.
• Diabetes requiring basal insulin supplementation: offers steady insulin exposure to reduce daily glucose excursions.

• Insulin Detemir binds to insulin receptors on peripheral tissues, stimulating glucose uptake into muscle and adipose cells, promoting glycogen synthesis in the liver, and suppressing hepatic glucose production. Its fatty‑acid side chain facilitates reversible albumin binding, resulting in a prolonged, relatively flat pharmacokinetic profile that delivers basal insulin activity over 24 hours.

Levemir Flextouch may be associated with several adverse reactions.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
• Injection‑site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase in body weight with chronic use.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Edema: mild peripheral swelling in some patients.
• Headache: occasional mild headache.

Serious or Rare Side Effects

• Severe hypoglycaemia: can lead to seizures, loss of consciousness, or injury.
• Allergic reactions: rash, urticaria, or angioedema.
• Anaphylaxis: rare but life‑threatening systemic hypersensitivity.
• Insulin antibody formation: may alter insulin effectiveness.
• Hypokalemia: low potassium levels in rare cases.
• Severe injection‑site necrosis: very uncommon tissue damage.

When using Levemir Flextouch, several safety considerations are important.

• Hypoglycaemia risk: monitor blood glucose regularly and adjust dose as needed.
• Renal impairment: consider dose reduction and close monitoring in patients with reduced kidney function.
• Pregnancy: use only if the expected benefit outweighs potential risk to the fetus.
• Elderly patients: initiate therapy at a low dose and titrate cautiously.
• Concomitant beta‑blockers: may mask hypoglycaemia symptoms, requiring vigilant glucose checks.
• Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Flextouch can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Beta‑blockers: may conceal hypoglycaemia warning signs.
• MAO inhibitors: can potentiate insulin’s glucose‑lowering effect.
• Alcohol: may enhance insulin action and increase hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may raise blood glucose, requiring dose adjustment.
• Corticosteroids: can increase insulin requirements.
• ACE inhibitors: may affect potassium balance, necessitating monitoring.
• Oral contraceptives: may slightly alter insulin sensitivity.
• NSAIDs: high doses may affect renal function and insulin clearance.